AstraZeneca’s Zomig patents upheld in precedential ruling

02-07-2018

AstraZeneca’s Zomig patents upheld in precedential ruling

mihailgrey / iStockphoto.com

The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.


Impax, Lannett, AstraZeneca, Par, inter partes review, Zomig, nasal spray, patent infringement, patent invalidation, prior art, obviousness, generics

LSIPR